All In Biotech

Drug Trial Radar · NCT02299999

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 1,460 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,460

Actual

Start

Apr 7, 2014

Primary completion

Dec 2022

Study completion Dec 2025

Sponsor

Lead sponsor
UNICANCERAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fondation ARC; AstraZeneca
First posted
Nov 24, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open label multicentric phase II randomized trial, using high throughput genome analysis as a therapeutic decision tool, which aims at comparing a targeted treatment administered according to the identified molecular anomalies of the tumor with maintenance chemotherapy (targeted substudy 1) as well as immunotherapy with maintenance chemotherapy in patients without actionable genomic alterations or non eligible to substudy 1 (immune substudy 2).

Conditions

  • Metastatic Breast Cancer

Interventions

  • AZD2014Drug

    Target: m-TOR

  • AZD4547Drug

    Target: EGFR

  • AZD5363Drug

    Target: AKT

  • AZD8931Drug

    Target: HER2, EGFR

  • SelumetinibDrug

    Target: MEK

  • VandetanibDrug

    Target: VEGF, EGFR

  • BicalutamideDrug

    target: Androgen receptor

  • OlaparibDrug

    Target: PARP

  • AnthracyclinesDrug

    DNA intercalation

  • TaxanesDrug

    Target: mitotic tubulin and microtubules

  • cyclophosphamideDrug

    Alkylating agents

  • DNA intercalatorsDrug

    DNA intercalators

  • MethotrexateDrug

    DNA intercalators

  • vinca alkaloidsDrug

    Target: mitotic tubulin and microtubules

  • Platinum based chemotherapiesDrug

    Platinum based chemotherapies

  • BevacizumabDrug

    Target: VEGF

  • Mitomycin CDrug

    Alkylating agents

  • EribulinDrug

    Microtubule modulator

  • MEDI4736Drug

    Target: PD-L1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival in the targeted drug arm compared to standard maintenance therapy armTime frame: from randomization to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Institut de Cancérologie de l'Ouest/Paul Papin

    Angers, France

  • Institut Sainte-Catherine

    Avignon, France

  • Polyclinique Bordeaux Nord Aquitaine

    Bordeaux, France

  • Institut Bergonié

    Bordeaux, France

  • Centre François Baclesse

    Caen, France

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • Centre Georges François Leclerc

    Dijon, France

  • Chd Vendee

    La Roche-sur-Yon, France

  • Centre Oscar Lambret

    Lille, France

  • Chu Dupuytren

    Limoges, France

  • Centre Hospitalier Lyon Sud

    Lyon, France

  • Centre Léon Bérard

    Lyon, France

  • Institut Paoli Calmettes

    Marseille, France

  • Institut Régional du Cancer Montpellier Val d'Aurelle

    Montpellier, France

  • Centre Alexis Vautrin

    Nancy, France

  • Institut de Cancérologie de l'Ouest/ René Gauducheau

    Nantes, France

  • Centre Antoine Lacassagne

    Nice, France

  • Institut Curie

    Paris, France

  • Centre Eugène Marquis

    Rennes, France

  • Centre Henri Becquerel

    Rouen, France

  • Institut Curie

    Saint-Cloud, France

  • Hopitaux Universitaire de Strasbourg - Hopital Civil

    Strasbourg, France

  • Hopitaux Du Leman

    Thonon-les-Bains, France

  • Institut Claudius Regaud

    Toulouse, France

  • Gustave Roussy

    Villejuif, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.